Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome  by Usberti, Mario et al.
Kidney International, Vol. 25 (1984), pp. 422—429
Role of plasma vasopressin in the impairment of water
excretion in nephrotic syndrome
MARIO USBERTI, STEFANO FEDERICO, SERGIO MECCARIELLO, BRUNO CIANCIARUSO,
MARIO BALLETTA, CARMINE PECORARO, LUIGI SACCA, BIAGI0 UNGARO, NICOLA PISANTI,
and VITT0RI0 E. ANDREUCCI
Department of Medical Nephrology, Pediatric Clinic, and Institute of Medical Pathology; and Institute of Pharmacology, Il Faculty of
Medicine and Surgery, University of Naples, Napoli, Italy
Role of plasma vasopressin in the impairment of water excretion in
nephrotic syndrome. To verify whether or not an increased secretion of
ADH may cause the water retention commonly observed in nephrotic
syndrome, 16 nephrotic patients and 13 normal control subjects were
studied in basal conditions and following a water load or an iso-osmotic
blood volume expansion by 20% albumin infusion. In the basal condi-
tion there were no differences in plasma ADH, urine output, urinary
osmolality (Uom), and plasma renin activity between nephrotic pa-
tients and control subjects; POEm, PNa, UNaV, and blood volume (BV)
instead, were significantly lower in nephrotic patients than in control
subjects. Following the water load control subjects reached a minimal
Uosm of 82 12 mOsm/kg at 60 mm and excreted completely the
ingested water in 150 mm; nephrotic patients reached a minimal U0sm of
160 111 mOsm/kg at 120 mm, and the water was eliminated
completely in 240 mm. Plasma ADH decreased significantly in the first
hour following water load only in control subjects. A significant direct
correlation was observed between plasma ADH and Pom in control
subjects (ADH = —85 + 0.30 P0,, P < 0.001) but not in nephrotic
patients. Plasma ADH was inversely correlated with BV in nephrotic
patients (ADH = 15.47 — 0.17 By, P < 0.001) but not in normal control
subjects. In nephrotic patients with reduced BV the expansion of BV
with 20% albumin was effective in reducing the plasma levels of ADH
and promoting a water diuresis. Our results demonstrate a sustained
volume mediated secretion of ADH in the nephrotic syndrome, which is
responsible for the impairment in water excretion.
ROle de Ia vasopressine plasmatique dans l'anomalie d'excrétion hy-
drique an cours du syndrome néphrotique. Afin de verifier si une
élévation de Ia secretion d'ADH peut ou non entraIner Ia retention
hydrique habituellement observée lors du syndrome nephrotique, 16
malades nephrotiques et 13 sujets contrôles normaux ont et étudiCs
dans des conditions basales et aprCs une charge hydrique ou une
expansion isoosmotique du volume sanguin par une perfusion de 20%
d'albumine. Dans le condition basale, il n'y avait pas des differences
dans l'ADH plasmatique, le debit urinarie, l'osmolalité urinaire (Uosm),
et l'activite rénine plasmatique entre les malades nephrotiques et les
sujets contrOles; POEm, PN', UNV, et le volume sanguin (BY) au
contraire, étaient significativement plus faibles chez les malades nCph-
rotiques que chez les sujets contrôles. Aprés Ia charge hydrique, les
sujets contrôles ont atteint une Uosm minimale de 82 12 mOsmlkg a 60
mm et ont excrété complètement l'eau ingéree en 150 mm; les malades
néphrotiques ont atteint une Uosm minimale de 160 111 mOsmlkg a
120 mm, et l'eau était completement Climinée en 240 mm. L'ADH
plasmatique a diminué significativement au cours de la premiere heure
aprés Ia charge hydrique, seulement chez les sujets contrôles. Une
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correlation directe significative a été observde entre I'ADH plasmatique
et Posm chez les sujets contrôles (ADH = —85 + 0,30 POsm, P < 0,001)
mais non chez les malades nephrotiques. L'ADH plasmatique Ctait
inversement corrélCe a BY chez les malades néphrotiques (ADH =
15,47 — 0,17 By, P < 0,001) mais non chez les sujets contrOles
normaux. Ches les malades nCphrotiques avec une diminution du
volume sanguin l'expansion de BV avec 20% d'albumine permettait de
rCduire les concentrations plasmatiques d'ADH et de promouvoir une
diurCse aqueuse. Nos résultats démontrent une secretion d'ADH per-
sistante dépendante du volume au cours du syndrome nephrotique,
laquelle est responsable de l'altération de I'excrétion hydrique.
Patients with nephrotic syndrome are often oliguric with a
low urinary concentration of sodium. This oliguric state is
commonly attributed to an increase in tubular reabsorption of
sodium. But hyponatremia and plasma hypo-osmolality are also
typical features of nephrotic syndrome, suggesting that in this
condition water is reabsorbed more avidly than sodium. The
mechanism(s) of this water retention, however, is unknown. It
has been suggested that a reduced plasma volume may cause
water retention in cirrhosis [1] and congestive heart failure [2]
possibly through an increased secretion of ADH. A similar
mechanism may therefore occur also in nephrotic syndrome [3,
4]. The present study was undertaken to verify if an increased
secretion of ADH may account for water retention in nephrotic
syndrome and, if it does, to characterize the stimuli for the
enhanced release of this hormone. The results clearly demon-
strate a sustained volume-mediated secretion of ADH in ne-
phrotic syndrome.
Methods
The study was performed in 29 subjects, 16 patients with
nephrotic syndrome and 13 with glomerulonephritis and/or
hematuria without nephrotic syndrome (control subjects); all of
them were normotensive with normal renal function. The
clinical features of all subjects are reported in Table 1. Nephrot-
ic syndrome was defined by the association of proteinuria,
(usually 3 g124 hr), hypoalbuminemia, hypercholesterolemia,
hypertrigliceridemia, and edema. None of the nephrotic pa-
tients had signs of tubulopathy. The subjects gave their in-
formed consent to participate in the study. Each nephrotic
subject under study had his urinary excretion of sodium mea-
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Table 1. Clinical features of all patients
Patient Age
no. Sex years Diagnosis
Proteinuria
g/24 hr Edema
Control subjects
1 M 8 DMGN 0.1 No
2 M 14 Persistent hematuria — No
3 F 8 FGN — No
4 F 7 DMGN 0.2 No
5 M 13 MCGN — No
6 F 10 FGN — No
7 M 12 Persistent hematuna 0.1 No
8 F 10 IgA-GN 0.2 No
9 M 8 Transient hematuria — No
10 M 37 Transient hematuria — No
11 M 42 Isolated hematuria — No
12 F 39 Persistent hematuria — No
13 F 34 FGN 0.2 No
Nephrotic patients
14 F 35 DMGN 10 ++++
15 F 13 DMGN 7 ++
16 F 18 MPGN 5 ++
17 F 43 MPGN 5 ++
18 M 8 MCGN 4 ++
19 F 10 MCGN 4 ++
20 M 6 MCGN 8 ++++
21 M 8 MCGN 3 ++
22 F 14 DMGN 12 +++
23 F 25 MPGN 14 ++++
24 F 12 FGS 20 ++++
25 M 8 MCGN 5 +++
26 F 8 MCGN 9 ++++
27 F 14 MCGN 4 ++
28 F 48 FGS 3 +
29 M 14 MCGN 2 +
Abbreviations: DMGN, diffuse mesangial proliferative glomerulo-
nephritis; FGN, focal glomerulonephritis; MCGN, minimal change
glomerulonephritis; MPGN, membranoproliferative glomerulonephri-
tis; FGS, focal glomerulosclerosis.
sured daily during a 5-day period while on a normally salted
diet; at the end of this period, sodium excretion ranged between
4 to 35 mEq/24 hr in most patients. Only four patients had a
greater sodium loss: 115 to 150 mEqI24 hr. Each nephrotic
subject then received a daily intake of sodium equal to his
urinary loss throughout the study. It was argued that sodium
balance was achieved when both body weight and sodium
excretion remained stable for at least 3 days. Control subjects
ate a normally salted diet. All drugs were stopped at least 10
days before the study while the use of alcohol, tobacco, tea, and
coffee was prohibited.
The urinary excretion of free epinephrine (E) and norepineph-
tine (NE) was measured over a 6-hr period, from 6 to 12 A.M.
the day before the clearance study. During this time the subject
was in bed, rising only to void. The clearance study was carried
out the next morning, after a fasting period of 12 hr. Free access
to water was permitted until 3 hr before the study. After 3 hr in
the bed, plasma volume and total blood volume (BY) were
measured by calculating the distribution space of '251-labelled
albumin as previously described [5]. Then a 1-hr clearance
period (basal clearance period) was performed with a collection
of urine by spontaneous voiding. Blood samples for creatinine,
osmolality, sodium, potassium albumin, ADH, and renin activi-
ty (PRA) were withdrawn in the middle of the clearance period.
After the basal clearance period, 11 nephrotic patients and 9
control subjects accepted to continue the study. They were
divided into two subgroups: One subgroup underwent a water
load study, and the other one was exposed to volume expansion
by plasma albumin.
Water load study
After the basal clearance period, five nephrotic patients
(numbered 14 to 18) and five control subjects (numbered 1 to 5)
were water-loaded by drinking 20 mI/kg body wt of water in 20
mm. Clearance periods were then carried out hourly until the
UIPosm ratio, after an initial decrease, rose to 1 or more. At this
time it was presumed that the whole ingested water had been
excreted. Plasma ADH and plasma osmolality were measured
30, 60, 90, 150, and 210 mm after the water ingestion. GFR was
measured as the clearance of inulin and renal plasma flow (RPF)
as the clearance of PAH.
Expansion study
The effect of expansion of BY on plasma ADH and water
excretion was studied in six nephrotic patients (numbered 22,
23, 26, 27, 28, and 29) and in four control subjects (numbered 10
to 13). After the basal clearance period, 3.3 mI/kg body wt of
20% human plasma albumin were infused intravenously in 15
mm. Plasma osmolality and plasma ADH were measured before
and 10 to 20 and 60 mm after the completion of the infusion.
BY, GFR, PRA, plasma albumin, urine output, urinary sodium,
and osmolality were determined before and 1 hr after the
infusion.
Urine and serum were analyzed for total solutes with an
osmometer (Fiske Associates, Uxbridge, Massachusetts) and
for sodium and potassium with an IL flamephotometer. The
clearances of creatinine, inulin, PAH, and free water were
calculated by conventional formulas. Urine specimens for cate-
cholamines were added to carboxylic acid ion-exchange resin
columns. The catecholamines were eluted with a boric acid
solution and determined fluorometrically (E + NE: 405 to 495
nm; E: 436 to 540 nm; NE by difference) after oxidation to a
trihydroxyindole derivate [6]. For the extraction of ADH 1 ml
of plasma (2 ml of plasma were used when the value of ADH
was below the sensitivity of the method) was mixed with 2 ml of
acetone; after centrifugation, the supernatant was removed and
mixed with 4 ml of petrolether. After vigorous agitation the
upper phase was removed and the lower phase was air-dried
and reconstituted in 1 ml of vasopressin diluent. Aliquots of 0.4
ml were used for immediate assay or frozen until analyzed [7].
This extraction procedure in our laboratory has a recovery of
70% 1%. ADH was measured by RIA [8] using a specific
antibody for 8-arginine-vasopressin obtained from the National
Institute of Arthritis, Metabolism and Digestive Disease, Wash-
ington, D.C. '25IArg(8)-vasopressin with a specific activity
greater than 1000 CiIy was obtained from the New England
Nuclear Corp., Boston, Massachusetts. The incubation time, in
buffer phosphate 0.2 M, pH 7.4, was 1.5 + 4.5 days. The B/F
separation was made using charcoal-dextran. The sensitivity of
RIA was 0.13 0.01 pg/tube, corresponding to a plasma
concentration of ADH of 0.46 pg/mI; the precision of RIA
expressed as intraassay and interassay cv, was 6 and 11%
respectively, at a vasopressin concentration of 2.6 pg/mI.
Measured ADH was linearly correlated to the volume of plasma
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TabIe 2. Basal values of a11 patients under study
Pa-
tient POEm
no. mOsm/liter
PNa
mEq/liter
Paib
gIdi
BV
mi/kg
ADH
pg/mi
PRA
ng/mi/hr
GFR RPF V
Uosm
mOsm/liter
UNaV
mEq/mmn
U UNE
pg/hrmi/mm
Control subjects
1 287 141 4.04 87.0 2.93 3.60 84 290 0.70 760 0.068 0 2.06
2 303 144 4.41 95.0 6.70 1.20 138 504 0.60 1100 0.120 0 3.19
3 285 139 4.67 101.0 1.47 3.70 88 289 1.00 600 0.085 0 2.23
4 285 140 4.30 83.3 2.07 3.06 106 254 1.20 616 0.226 0 1.50
5 292 143 4.01 84.5 4.06 3.40 130 575 0.70 730 0.077 0 2.10
6 285 137 3.80 90.0 1,48 2.00 95 — 0.75 550 0.061 0 0.93
7 298 144 4.20 94.9 5.16 0.50 88 — 0.62 910 0.104 — —
8 286 141 3.70 81.0 0.44 0.85 105 — 0.57 520 0.060 0.01 1.75
9 285 137 4.02 92.0 0.44 0.80 98 — 0.80 596 0.101 0.16 0.86
10 287 141 4.10 78.0 1.50 3.72 193 — 2.43 541 0.248 0.10 1.89
11 297 141 3.80 76.5 3.30 0.56 114 — 0.31 994 0.043 0.38 1.16
12 285 141 3.60 71.6 3.03 1.60 76 — 0.47 885 0.078 — —
13 286 137 3.37 73.5 3.73 4.46 106 — 0.25 841 0.054 — —
Mean 289.1 140.4 4.00 84.5 2,79 2.26 109.3 382.0 0.80 741.8 0.102 0.065 1.76
SE 1.7 0.7 0.09 2.9 0.51 0.40 8.5 65.4 0.15 52.8 0.018 0.039 0.22
Nephrotic patients
14 279 131 1.05 66.5 5.05 7.80 72 227 0.53 550 0.002 0.12 2.96
15 283 138 1.80 70.1 3.31 1.70 87 399 0.53 860 0.100 0.13 2.75
16 284 136 1.52 67.0 4.38 4.86 134 677 0.70 897 0.117 0.33 1.04
17 282 137 1.69 77.0 2.40 0.46 145 558 1.37 457 0.107 0.33 3.38
18 286 138 1.30 70.5 3,10 1.50 110 295 0.33 933 0.086 0.14 1.81
19 282 137 1.70 72.0 2.60 1.50 96 — 0.50 680 0.020 0.46 1.32
20 276 133 1.10 59.0 8.34 9.10 130 — 0.25 1160 0.001 0.13 1.37
21 285 140 1.76 79.0 2.20 1.10 139 — 0.45 756 0.005 0.40 1.71
22 285 140 1.57 66.5 2.80 3.68 114 — 0.45 655 0.027 0.44 1.71
23 274 135 1.09 62.0 2.40 15.40 96 — 0.29 886 0.001 0.25 1.56
24 276 135 1.50 72.0 3.10 2.30 85 — 0.49 690 0.003 0.04 0.49
25 278 134 1.60 67.0 3.70 16.80 135 — 0.22 1080 0.001 — —
26 281 137 1.07 61.7 4.00 8.75 68 — 0.52 466 0.027 — —.-
27 282 136 1.91 73.0 3.30 2.85 88 — 0.42 750 0.002 — —
28 283 135 2.11 75.3 2.30 2.13 83 — 0.37 800 0.005 —
29 280 137 1.75 68.0 3.53 2.81 90 — 0.47 575 0.050 — —
Mean 281a 136.2a 1.53a 69,2a 3.53 5.17 104.5 431.2 0.50 762.2 0.036b 0.25 1.87
SE 0.89 0.59 0.08 1.39 0.38 1.26 6.31 83.0 0.07 50.7 0.010 0.04 0.26
Abbreviations: POsm, plasma osmolality; PNa, plasma sodium concentration; Paib, plasma albumin concentration; By, blood volume; ADH,
antidiuretic hormone; PRA, plasma renin activity; GFR, glomerular filtration rate; RPF, renal plasma flow; V, volume; U0, urinary osmolality;
UNaV, urinary excretion of sodium; UE, urinary excretion of epinephrine; UNE, urinary excretion of norephinephrine.
P < 0.001
P < 0.005
P < 0.01
extracted, and recovery of internal standard added to the
plasma was almost complete (96 3%) and independent from
the volume extracted. The statistical analysis was performed by
the unpaired Student's (test and the multiple linear regression
analysis; multiple comparisons were made by the analysis of
variance and the Dunnett's procedure. Data are presented as
mean SE.
Results
Table 2 summarizes the parameters recorded in basal condi-
tion. Plasma osmolality, sodium and albumin, blood volume,
and urinary sodium excretion were significantly lower in ne-
phrotic patients. There was no difference, instead, in GFR,
RPF, PRA, urine output, and Usm between nephrotic patients
and control subjects. Nephrotic patients showed a greater
urinary excretion of free epinephrine; the greater plasma con-
centration of ADH, instead, was not statistically significant.
The results of the water load study are reported in Table 3.
Control subjects diluted the urine samples maximally 60 mm
after the water load (82.6 8.23 mOm/kg, P < 0.01). The
ingested water was completely eliminated in 150 mm; at this
time the urine output (1.76 0.45 ml/min) was not different
from basal values and the U/P0sm ratio (1.45 0.24) was greater
than 1 in four subjects and was 0.995 in the fifth one. The CH2O
rose from a negative basal value of —1.25 0.10 mllmin to
+7.23 1.78 ml/min (P < 0.01) after 60 mm and decreased to
negative values at 150 mm. Plasma ADH fell from 3.79 0.9
pglml to 2.53 0.88 pg/mi (P < 0.05) and to 2.33 0.79 pg/mi
(P < 0.05), respectively, 30 and 60 mm after the water load.
Nephrotic patients reached a minimal U0sm of 160.8 49.9
mOsm!kg (range, 85 to 350) (P < 0.01) 120 mm after the water
load. The ingested water was eliminated completely in 240 mm.
The CH2O rose from —0.94 0.16 mllmin to +1.12 0.14,
+2.85 1.25 (P < 0.01), +1.90 1.22 mllmin (P < 0.05) 60,
120, and 180 mm, respectively, after the water load. After 240
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mm the CH2O decreased to negative values in patients 16 and 18
but was still slightly positive in patients 15 and 17. Only one out
of five nephrotic patients (number 14) was unable to produce
free water after the water load; the patient had the lowest value
of plasma sodium (131 mEq/liter). Plasma ADH did not change
in nephrotic patients after the water load. No difference in
plasma ADH was observed between control subjects and
nephrotic patients at any time although plasma osmolality in
nephrotic patients was significantly lower than in controls at 30,
60, 90, and 150 mm after the water load.
The results of the expansion study are reported in Table 4.
The rapid intravenous infusion of 3.3 mi/kg body wt of 20%
albumin did not modify plasma osmoiality nor the plasma
concentration of sodium but lead to a 17% increase of blood
volume in control subjects and to a 15% increase of blood
volume in nephrotic patients. In control subjects the urine
output rose (from 0.86 0.52 to 1.59 0.39; P < 0.05), Uosm
exhibited an insignificant decrease. CH2O factored from 100 ml
of GFR did not change. GFR and urinary sodium excretion
increased significantly. No significant changes were observed
in plasma ADH.
Four out of six nephrotic patients (numbered 22, 23, 26, and
29) undergoing the expansion study had low basal values of
blood volume, which were very low in patients 23 and 26. Blood
volume in the nephrotic patients 27 and 28, instead, was similar
to that found in some control subjects. The rapid intravenous
infusion of 20% albumin increased the mean urine output of
nephrotic patients significantly (from 0.43 0.04 to 4.28
1.02 mllmin, P < 0.05) and decreased Uosm (P < 0.005)
significantly. The mean value of CH2O, factored for 100 mIIGFR
increased from —0.64 0.05 to +1.9 0.95 mllmin (P <0.05).
However, the diuretic effect of blood volume expansion was
less marked in the two patients with normal blood volume: The
urine output rose from 0.42 to 2.52 ml/min in patient 27 and
from 0.37 to 1.50 ml/min in patient 28. Accordingly, in these
patients the urinary osmolality decreased less, from 750 to 375
and from 800 to 410 mOsm/kg, respectively, without production
of free water. When the mean value of CH2O/GFR x 100 was
calculated again for the four patients with severe BY reduction,
a greater increase was observed following BY expansion (from
—0.57 0.04 to + 3.23 0.71 mllmin, P < 0.005). After 20%
albumin infusion, plasma ADH fell significantly as a mean of all
six patients. In the four patients with the lowest blood volume
the fall in plasma ADH was greater, going from a mean basal
value of 3.18 0.36 pg/mi to 1.74 0.52 (P<0.02), 1.29 0.4
(P <0.005), and 1.5 0.26 pg/mi (P < 0.01) after 10,20, and 60
mm, respectively. There was no significant difference in the
mean plasma ADH values between control subjects and the six
nephrotic patients, although plasma ADH fell below I pglml in
two nephrotic patients after the expansion. GFR and urinary
sodium excretion increased significantly after blood volume
expansion.
When the values of Osm obtained before and after the water
load were plotted against the respective values of plasma ADH,
a highly significant correlation was observed in control subjects
(ADH = 85 + 0.30 Posm) (Fig. 1) but not in nephrotic patients
(Fig. 2). In the latter the secretion of ADH was not reduced
during the water load, despite very low values of plasma
osmolality. As shown in Figure 3 in nephrotic patients plasma
ADH was inversely correlated with blood volume (ADH =
15.47 — 0.17 BY); this correlation was not observed in control
subjects. A multiple regression calculated between plasma
ADH, plasma osmolality, and BY clearly demonstrates that
plasma ADH was regulated by plasma osmolality in non-
nephrotic subjects (ADH = —69.085 + 0.256 POsm — 0.023 BY;
t P0sm = 4.775, P < 0.001; t BY = —0.625, P = NS) and by BY
in nephrotic patients (ADH 20.23 — 0.016 Osm — 0.174 BY; t
POsm =
—0.159, P = NS; t BY = —2.64, P < 0.01). A direct
relationship between BY and plasma albumin concentration
was observed both in nephrotic patients (BY = 49.29 + 12.96
Paib, r = 0.758, P < 0.001) and in control subjects (BV = 3.66 +
20.39 Pb, r = 0.79, P < 0.01), while an inverse relationship
between PRA and BY was detected in nephrotic patients only
(PRA = 48.3 — 0.62 BY, r =
—0.68, P < 0.01). In both
nephrotic patients and control subjects no correlation was
found between plasma ADH and PRA, between plasma ADH
and urinary E or NE, between urinary catecholamines and BY,
and between urinary E or NE and sodium excretion.
Discussion
An impairment in renal water excretion resulting in hypona-
tremia and hypo-osmolality occurs in most nephrotic patients.
The mechanism responsible for this water retention has not
been fully clarified as yet. Recent studies in patients with
nephrotic syndrome [3, 4], cirrhosis [I], or congestive heart
failure [2] have given some evidence in favor of a key role of a
reduction in effective blood volume on the abnormal water
retention.
One of the major difficulties in studying this problem in
nephrotic patients is the correct measurement of blood volume
[3]. The different reliability of the methods used for blood
volume measurement may account for the different results
reported in the literature [9—I l}. In the present study we have
expressed the blood volume in milliliters per kilograms of wet
weight which may account for our finding that none of the
nephrotic patients had an increased blood volume. This finding
is in contrast with the results of other studies [4, 10, lii. Blood
volume was in fact low in eight of our patients, normal in six,
and border line in two. The expansion of extracellular volume
which is typical of edematous nephrotic patients may account
for the discrepancies in blood volume determination when the
latter is referred to dry weight [4, 11], to wet weight (the present
study), or it is not corrected at all for body weight [10]. Blood
volume referred to wet weight was in our opinion sufficiently
representative of the volemic status of the subjects under study,
since a linear relationship between blood volume and plasma
albumin concentration was observed both in control subjects
and nephrotic patients. An inverse relationship was found only
in nephrotic patients between blood volume and PRA. On the
other hand, in our opinion it is more correct to express blood
volume in percent of wet weight since the degree of ECY
expansion may greatly influence blood volume [12].
The inverse relationship observed in nephrotic patients be-
tween blood volume and PRA substantially agrees with the
observations of Meltzer et al [11], which suggest that nephrotic
patients with low renin have a high plasma volume and nephrot-
ic patients with high renin have a relatively low plasma volume.
Patients we studied with nephrotic syndrome clearly exhibit-
ed a delayed and impaired excretion of a water load (Table 3).
This nhenomenon was nartieiilarlv vidnf in th-se ntipnt
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Table 3. Excretion of a water load in five control (C) and five nephrotic (N) subjects; values are the means SE
Abbreviations are the same as those used for Table 2.
a p < 0.001 (versus basal values)
b P < 0.005 (versus basal values)
P < 0.01 (versus basal values)
d p < 0.02 (versus basal values)
a p < 0.05 (versus basal values)
with very low blood volume. In fact, in nephrotic patients only
120 mm after the water load urine osmolality reached the lowest
value (160.8 49.9 mOsmlkg). In control subjects urine dilution
was greater (Uosm = 82.6 8.2 mOsm/kg) and occurred earlier
P < 0.01 (nephrotic versus control subjects)
d P < 0.02 (nephrotic versus control subjects)
P < 0.05 (nephrotic versus control subjects)
P < 0.001 (nephrotic versus control subjects)
g P < 0.005 (nephrotic versus control subjects)
h p < 0.01 (nephrotic versus control subjects)
'P < 0.02 (nephrotic versus control subjects)
i P < 0.05 (nephrotic versus control subjects)
Basal
Water load
30 mm 60 mm 90 mm 120 mm 150 mm
V. mi/mm
C
N
U0,,, mOsm/kg
C
N
CH2O, mi/mm
C
N
PNa, mEq/iiter
C
N
POsm, mOsm/kg
C
N
Plasma ADH, pg/mi
C
N
GFR, mi/mm
C
N
RPF, mi/mm
C
N
0.84 0.11
0.69 0.18
761.2 90.2
739.4 98.1
—1.25 0.10
—0.94 0.16
141.4 0.92
136.0 l.30
290.4 3.40
282.2 1.16
3.79 0.90
3.65 0.47
109.0 10.8
107.0 15.2
382.0 65.4
431.0 83.0
137.4 0.68a
133.8 1.74°
287.0 33Qb
276.6 1.08°°
2.53 0.88"
3.50 0.24
10.04
3.08
82.6
226,4
+7.23
1.12
137.2
134.2
287.4
276.2
2.33
2.88
113.8
98.4
524.0
442.0
2.26°
1.06d
8.23a
47,5a.d
1.78°
0.74d
0.62°
1.50b
3.10
3.28°°
0.79"
0.40
14.2
8.8
106.5
50.3
139.0 0.68"
134.8 1.50°
288.4 2.23
277.8 334b.o
3.07 0.99
3.40 0.66
6.22 1.31"
4.52 1.71°
135.6 19.9°
160.8 49.9°
+3.68 1.02"
+2.85 1.25°
113.2 15.2
106.0 9.9
455.0 66.0
469.0 70.5
1.76 0.45
419.8 67.7a
—0.42 0.22
140.0 0.55
135.2 1.3
289.8 2.3
280.2 3.15°
3.88 0.74
3.54 0.22
Abbreviations are the same as those for Table 2.
a P < 0.01 (differences from basal values)
b p < 0.05 (differences from basal values)
Table 4. Effects of iso-osmotic expansion of blood volume with plasma albumin in six nephrotic (N) and four control (C) subjects;
values are means SE
Subject Basal
Blood volume expansion by iv. infusion
3.3 mi/kg body wt
of 20% plasma albumin,
10 mm 20 mm 60 mm
POSm, mOsm/kg C
N
288 3
281 2
288 3
280 2i
289 3
281 1'
288 3
281 li
ADH, pg/mi C
N
2.89 0.48
3.05 0.27
2.19 0.62
1.70 0.33°
2.96 0.61
1.61 0.33°
2.03 0.44
1.64 0.22°
By, mi/kg C
N
75 1
68 2
88 2"
78 2°"
V, mi/mm C
N
0.86 0.52
0.43 0.04
1.59 0.39°
4.28 1.02°
Uosm, mOsm/kg C
N
815 97
689 63
652 51
203 61"
CH20/GFR x 100, mi/mm C
N
—0.87 0.20
—0.64 0.05
—1.06 0.13
+1.90 0.95e,i
UNaV, mEq/min C
N
0.106 0.047
0.018 0.007i
0.263 0.043"
0.149 0.049°
GFR, mi/mm C
N
122 25
90
173 14°
104
(60 mm after the water load). At 30 to 60 mm plasma osmolality
exhibited the lowest values both in control subjects and in
nephrotic patients, but plasma ADH decreased significantly
only in the former. Taken together our results clearly demon-
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180 mm 210 mm 240 mm
3.66 1.5" 1.61 0.54
269 94.9k 341.4 74.8
+1.90 1.22" —0.002 0.25
135.6 1.48
281.2 3.21
3.20 0.41
Fig. 2. Absence of correlation between plasma ADH and plasma
osmolality in nephrotic patients. Solid circles represent the basal values
of those patients not submitted to the water load. Patients who received
the water load are represented by the following symbols: 0, patient no.
14; , patient no. 15; 0, patient no. 16; A, patient no. 17; , patient no.
18.
stimulates ADH secretion; an inverse correlation between
blood volume and plasma ADH levels was, in fact, observed in
nephrotic patients (Fig. 3) but not in non-nephrotic control
A subjects. The iso-osmotic expansion of blood volume wasD followed by a sustained inhibition of ADH (Table 4) and by a
water diuresis in those nephrotic patients who exhibited a
severe reduction in blood volume. After 20% albumin infusion
250 260 270 280 290 300 310 urine output also rose in the two nephrotic patients with normal
blood volume and in non-nephrotic control subjects, but these
subjects remained unable to produce free water, since their
plasma levels of ADH were only slightly reduced (Table 4).
Other intrarenal factors may undoubtedly contribute to the
impairment in water excretion of nephrotic syndrome. Thus, an
enhanced proximal tubular reabsorption may reduce free water
formation through a decrease in distal delivery and increase free
water back diffusion from the collecting duct due to the
prolonged transit time along the nephron. Whether proximal
tubular reabsorption is enhanced [9, 13, 14] or reduced [15—17]
in nephrotic syndrome, however, is still a matter of controver-
sy; our results are not contributory in this regard. Recent
experimental studies in rats, however, seem to support the view
Table 3. (Continued) 9
.
8
7
6
0
0
I.
0 0
Co 0 ••Co
Co
0 A••0
3. A.& •0
SA5
2-
ci1.
0/I 1 I
250 260 270 280 290 300
y = --85 + 0.30x
0.88 P<O.001
0
7
6
5
I0
Co
E
Co
Co0
2
0
A Plasma osmolality, mOsm/kg
3.
A
0
A
-_-D_'•_
Plasma osmolality. mOsm/kg
Fig. 1. Relationship between plasma ADH and plasma osmolality in
control subjects. Solid circles represent the basal values of the subjects
not submitted to the water load. Subjects who received the water load
are represented by the following symbols: 0, patient no. 1; 0, patient
no. 2; 0, patient no. 3; A, patient no. 4; A, patient no. 5.
strate that ADH release is regulated by plasma osmolality in
normal subjects (Fig. 1) but not in patients with nephrotic
syndrome (Fig. 2). In the latter ADH secretion was not inhibit-
ed by a water load, despite very low values of plasma osmolali-
ty. In nephrotic patients it is the reduced blood volume which
428 Usberti et a!
BV, mi/kg
Fig. 3. Relationship between plasma ADH and blood volume (BV) in
nephrotic subjects. Solid circles represent the basal values of nonex-
panded patients; the patients who underwent the BV expansion with
20% plasma albumin are represented by the following symbols: 0,
patient no. 22; +,patient no. 23; A, patient no. 26; , patientno. 27;•,
patient no. 28; 0, patient no. 29.
that in nephrotic syndrome proximal tubular reabsorption is, in
fact, reduced [18].
Salt retention was undoubtedly observed in nephrotic pa-
tients (Table 2), which was reversed by blood volume expan-
sion (Table 4), but the site of sodium reabsorption cannot be
established.
Presumably also alterations in renal hemodynamics do not
occur in nephrotic syndrome possibly accounting for the im-
pairment in renal handling of water; in our study no significant
difference in GFR and RPF was observed between nephrotic
patients and control subjects (Table 2). Thus, presumably not
only in cirrhosis [1, 19] and congestive heart failure [2], but also
in nephrotic syndrome, changes in renal hemodynamics or
intrarenal factors should play, if any, only a secondary role in
water retention.
Extrarenal factors other than blood volume have been sug-
gested to modulate the nonosmotic release of ADH, particularly
angiotensin II [20] and catecholamines [21, 221. In this study we
have not measured plasma levels of angiotensin II. We pre-
sume, however, that they were higher in nephrotic patients than
in control subjects since PRA was greater in the former (Table
2) and was corrected by blood volume expansion. We have
observed an inverse relationship between PRA and BV in
nephrotic patients but not in control subjects. No correlation,
however, was observed between plasma ADH and PRA. These
data therefore do not seem to support a role of the renin-
angiotensin system in regulating ADH release in nephrotic
syndrome.
Schrier and Berl [21] and Schrier, Lieberman, and Ufferman
[22] have demonstrated that alpha-adrenergic stimulation
causes and beta stimulation inhibits water diuresis by suppress-
ing and stimulating, respectively, the release of ADH with a
baroreceptor mechanism. In this study we have evaluated the
production of catecholamines in the subjects under study by
measuring their urinary excretion. Only epinephrine excretion
was increased in nephrotic patients. However, there was no
correlation between urinary E and blood volume, sodium
excretion, or plasma ADH. Whatever the cause of the increased
urinary epinephrine in our nephrotic patients, the adrenergic
system does not seem to represent an important factor in the
regulation of ADH release in nephrotic syndrome.
In conclusion, our study has given the first clear demonstra-
tion that the impairment in water excretion frequently observed
in nephrotic syndrome is due to a sustained, volume-mediated
secretion of ADH secondary to a severe reduction of blood
volume. Other factors, such as intrarenal mechanisms, renin-
angiotensin system, and catecholamines do not seem to play an
important role.
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